Genome sequences and proteomic data are becoming available to
researchers for an increasing number of normal genes and
different pathologies. Characterization of these genomes and
proteomes will be critical for the proper evaluation and
treatment of disease. DNA microarrays, chemical genomics
(proteomics), pharmacological genomics (proteomics), and
bioinformatics can be used to achieve these goals. This article
discusses how traditional and novel chemical and pharmacological
techniques for genomics and proteomics can be used to treat
disease and enhance drug discovery and development. Figure 1 -
Potential B-DNA to Z-DNA transition that occurs in some ds-DNA
sequences. This process can be regulated by DNA binding
proteins. Right-handed double-stranded (ds) B-DNA has a smooth
backbone with major and minor grooves. On the other hand, left-
handed ds-Z-DNA has only a minor groove. This figure represents
structural transitions that occur in conventional ds-DNA and
result in alternative structures. (Reproduced with